Taghighlights

Open letter to the EMA

Just back from ECTRIMS 2019 in Stockholm. My highlight was the alemtuzumab 8-year longterm extension data; the brain volume data is quite extraordinary (figure 5). In short, apart from HSCT, there is nothing that comes close to alemtuzumab in radically slowing-down or preventing end-organ damage. Comi et al. Alemtuzumab improves clinical and MRI disease activity outcomes, including slowing of...

Translate

Categories

Recent Posts

Recent Comments

Archives